At Affimed, we are committed to improving outcomes for patients with cancer. Our scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unique approach to fighting cancer. With our unparalleled expertise in innate immunity and innate cell engager-based medicines, we aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies. Source
No articles found.
DarioHealth Corp. (NASDAQ: DRIO) is a leading global Digital Therapeutics (DTx) co...
DarioHealth Corp. (NASDAQ: DRIO) is a leading g...
We are a commercial-stage biotech company focused on harnessing the inherent biolo...
We are a commercial-stage biotech company focus...
Allenaâs lead product candidate, reloxaliase, is a first-in-class, oral enzyme t...
Allenaâs lead product candidate, reloxaliase,...
Following two acquisitions of Creagh Medical and NorMedix â recognized innovator...
Following two acquisitions of Creagh Medical an...
Champions Oncology, Inc. is engaged in the development of advanced technology solu...
Champions Oncology, Inc. is engaged in the deve...
TransMedics is a commercial-stage medical technology company transforming organ tr...
TransMedics is a commercial-stage medical techn...
Trovagene is a clinical-stage, oncology therapeutics company, taking a precision m...
Trovagene is a clinical-stage, oncology therape...
Forty Seven is a clinical-stage immuno-oncology company focused on developing nove...
Forty Seven is a clinical-stage immuno-oncology...
Established in 2007, and headquartered in Wakefield, Massachusetts, Innovation Pha...
Established in 2007, and headquartered in Wakef...
Join the National Investor Network and get the latest information with your interests in mind.